Logo

'Adverse Market Conditions' Prompt Caprion to Withdraw IPO

Jul 28, 2006
NEW YORK (GenomeWeb News) - Caprion Pharmaceuticals has withdrawn its initial public offering due to “adverse market conditions,” the company said today.
 
Drug makers use the company’s CellCarta product, a proteomics technology, to profile proteins in solid tissues and plasma for disease-target identification and predictive medicine.
 
The technology relies on sample prep and purification, mass spectrometry analysis, quantitative expression of protein peptides, and bioinformatics-based protein identification.
 

Additional details were not provided.

Breaking News
The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.